08 February 2021 : Clinical Research
Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models
Ming Chen1BCE, Ting Ma1CDE, Jun Li1AEG*, Hai-Jun Zhang2D, Qiang Li3F, Jia-Jia Wang1F, Tian Sang1B, Chun-Li Cao1D, Xin-Wu Cui4AEFDOI: 10.12659/MSM.929913
Med Sci Monit 2021; 27:e929913
Table 3 Diagnostic value of clinical parameters and logistic regression models in predicting PCa and CS-PCa.
| Parameter | BPH group vs PCa group | NCS-PCa group vs CS-PCa group | ||||||
|---|---|---|---|---|---|---|---|---|
| AUC (95% CI) | Cut-off value | z statistic | P | AUC (95% CI) | Cut-off value | z statistic | P | |
| Age (years) | 0.58 (0.50, 0.65) | 75 | 1.79 | 0.07 | 0.51 (0.39, 0.63) | 78 | 0.14 | 0.89 |
| tPSA (ng/ml) | 0.56 (0.48, 0.63) | 7.63 | 1.38 | 0.16 | 0.56 (0.43, 0.67) | 6.16 | 0.81 | 0.42 |
| f/t PSA | 0.68 (0.61, 0.75) | 0.20 | 4.62 | <0.01 | 0.55 (0.43, 0.68) | 0.15 | 0.72 | 0.47 |
| PSAD (ng/ml·cm) | 0.68 (0.62, 0.75) | 0.18 | 4.54 | <0.01 | 0.83 (0.73, 0.91) | 0.20 | 7.20 | <0.01 |
| DRE | 0.53 (0.46, 0.61) | – | 1.81 | 0.07 | 0.54 (0.42, 0.66) | – | 0.96 | 0.34 |
| TRUS | 0.52 (0.45, 0.60) | – | 0.57 | 0.56 | 0.54 (0.42, 0.66) | – | 0.61 | 0.54 |
| mpMRI | 0.69 (0.62, 0.77) | – | 4.87 | <0.01 | 0.67 (0.54, 0.77) | – | 2.70 | <0.01 |
| Logistic Model | 0.79 (0.73, 0.84) | 0.36 | 8.58 | <0.01 | 0.87 (0.77, 0.93) | 0.50 | 8.87 | <0.01 |
| PCa – prostate cancer; NCS-PCa – nonclinically significant prostate cancer; CS-PCa – clinically significant prostate cancer; PSA – prostate-specific antigen; tPSA – total PSA; f/t PSA – free/total PSA; PSAD – PSA density; DRE – digital rectal examination; TRUS – transrectal ultrasound; mpMRI – multiparametric magnetic resonance imaging; AUC – area under receiver operating characteristic curve; CI – confidence interval. ‘−’ – Not applicable. | ||||||||